^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr del(11q)

    Apply
    Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE) (NCT04008706)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    09/17/2019
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    TP53 • CD20 • IGH • CD5 • FCER2
    |
    Chr del(17p) • Chr del(11q) • IGH mutation
    |
    Calquence (acalabrutinib)
    Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT04169737)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    07/29/2020
    Primary completion :
    07/09/2026
    Completion :
    07/09/2026
    TP53 • IGH
    |
    TP53 mutation • Chr del(11q)
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes (NCT04802161)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    08/24/2022
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    RUNX1 • SF3B1 • ASXL1 • SRSF2 • BCOR • U2AF1 • STAG2 • ZRSR2
    |
    Chr del(11q)
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation) • pomalidomide • thalidomide
    Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia (NCI-2016-00797) (NCT02756897)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    01/31/2025
    Initiation :
    07/07/2016
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    TP53 • IGH
    |
    TP53 mutation • Chr del(11q)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL (NCT03524235)
    Phase 1
    Noah Merin
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    07/18/2018
    Primary completion :
    11/07/2021
    Completion :
    11/01/2031
    MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B
    |
    Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression
    |
    Rituxan (rituximab) • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD)
    Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT02518555)
    Phase 2
    Jennifer Woyach
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    01/12/2016
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    TP53
    |
    Chr del(11q) • Chr del(17)(p13.1)
    |
    Imbruvica (ibrutinib)
    Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies (NCT01203722)
    Phase 1/2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    09/01/2010
    Primary completion :
    09/01/2025
    Completion :
    12/01/2025
    FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)
    |
    cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous
    CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML (NCT04620681)
    Phase 1/2
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/08/2024
    Initiation :
    01/14/2021
    Primary completion :
    08/10/2024
    Completion :
    08/10/2024
    JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2
    |
    TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)
    |
    cytarabine
    A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL (NCT01750567)
    Phase 2
    University of Michigan Rogel Cancer Center
    Active, not recruiting
    Last update posted :
    08/31/2023
    Initiation :
    11/01/2012
    Primary completion :
    05/01/2024
    Completion :
    05/01/2024
    CD20 • CD5 • FCER2
    |
    CD20 positive • Chr del(11q)
    |
    metformin
    Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia (SWOG-C10404) (NCT00602459)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    05/22/2023
    Initiation :
    01/15/2008
    Primary completion :
    12/01/2014
    Completion :
    04/15/2023
    CD20 • CD4 • CD5 • FCER2
    |
    Chr del(11q)
    |
    Rituxan (rituximab) • lenalidomide • cyclophosphamide • fludarabine IV • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • cyclophosphamide intravenous • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)
    Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) (GENUINE) (NCT02301156)
    Phase 3
    TG Therapeutics, Inc.
    Completed
    Last update posted :
    05/20/2022
    Initiation :
    01/27/2015
    Primary completion :
    04/01/2020
    Completion :
    04/01/2020
    TP53
    |
    TP53 mutation • Chr del(11q)
    |
    Imbruvica (ibrutinib) • Briumvi (ublituximab-xiiy)
    A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (iLLUMINATE ) (NCT02264574)
    Phase 3
    Pharmacyclics LLC.
    Completed
    Last update posted :
    09/21/2020
    Initiation :
    10/06/2014
    Primary completion :
    03/26/2018
    Completion :
    09/03/2019
    TP53 • IGH
    |
    TP53 mutation • Chr del(11q) • TP53 mutation + Chr del(17p) • IGH mutation
    |
    Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Leukeran (chlorambucil)